PE20230110A1 - Procesos para la preparacion de un inhibidor de cinasa - Google Patents

Procesos para la preparacion de un inhibidor de cinasa

Info

Publication number
PE20230110A1
PE20230110A1 PE2022002513A PE2022002513A PE20230110A1 PE 20230110 A1 PE20230110 A1 PE 20230110A1 PE 2022002513 A PE2022002513 A PE 2022002513A PE 2022002513 A PE2022002513 A PE 2022002513A PE 20230110 A1 PE20230110 A1 PE 20230110A1
Authority
PE
Peru
Prior art keywords
compound
formula
processes
preparation
kinase inhibitor
Prior art date
Application number
PE2022002513A
Other languages
English (en)
Inventor
Frenel Demorin
Khalid Shah
Sagar Shakya
Yong Wang
Wei Xu
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of PE20230110A1 publication Critical patent/PE20230110A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines

Abstract

REFERIDO A UN PROCESO PARA PREPARAR UN COMPUESTO DE FORMULA (I) O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE ESTE, QUE COMPRENDE PONER EN CONTACTO UN COMPUESTO DE FORMULA (II) CON UN COMPUESTO DE FORMULA (III), EN PRESENCIA DE UN SOLVENTE QUE ES ES UNA MEZCLA DE AGUA Y UN SOLVENTE ORGANICO TAL COMO ACETONA, ACETONITRILO, DIMETILFORMAMIDA, 1,4-DIOXANO O TETRAHIDROFURANO, Y UNA BASE QUE SE SELECCIONA DE NaOH, Na2CO3, K2CO3, NaHCO3 Y KHCO3; EN DONDE LG ES UN GRUPO SALIENTE, R1, R2, R3, R4, R5a, R5b, R5c, w, y, x Y z SON TAL COMO SE DEFINEN EN LA DESCRIPCION. EN DICHO PROCESO EL COMPUESTO DE LA FORMULA (III) SE AGREGA A UNA SOLUCION DE UN COMPUESTO DE LA FORMULA (II) DURANTE UN PERIODO DE AL MENOS 30 MINUTOS, CUYA TEMPERATURA DE REACCION SE MANTIENE DE 20 A 25 °C. DICHO COMPUESTO DE FORMULA (I) ES INHIBIDOR DE C-MET.
PE2022002513A 2020-04-30 2021-04-30 Procesos para la preparacion de un inhibidor de cinasa PE20230110A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063017739P 2020-04-30 2020-04-30
PCT/US2021/030035 WO2021222673A1 (en) 2020-04-30 2021-04-30 Processes for the preparation of a kinase inhibitor

Publications (1)

Publication Number Publication Date
PE20230110A1 true PE20230110A1 (es) 2023-01-25

Family

ID=76076455

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022002513A PE20230110A1 (es) 2020-04-30 2021-04-30 Procesos para la preparacion de un inhibidor de cinasa

Country Status (16)

Country Link
US (1) US20230192619A1 (es)
EP (1) EP4143169A1 (es)
JP (1) JP2023524692A (es)
KR (1) KR20230005190A (es)
CN (1) CN115461328A (es)
AU (1) AU2021263474A1 (es)
BR (1) BR112022021712A2 (es)
CA (1) CA3176042A1 (es)
CL (1) CL2022003008A1 (es)
CO (1) CO2022015205A2 (es)
CR (1) CR20220551A (es)
IL (1) IL297684A (es)
MX (1) MX2022013528A (es)
PE (1) PE20230110A1 (es)
TW (1) TW202208335A (es)
WO (1) WO2021222673A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3088200A1 (en) * 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
TW202334090A (zh) * 2021-11-03 2023-09-01 美商艾克塞里克斯公司 用於治療激酶依賴性病症之化合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201609324UA (en) * 2010-07-16 2017-01-27 Exelixis Inc C-met modulator pharmaceutical compositions
CA3088200A1 (en) * 2018-01-26 2019-08-01 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
CR20210375A (es) * 2018-12-13 2021-08-18 Exelixis Inc Formas cristalinas y formas de sal de un inhibidor de cinasa
CN109761899B (zh) * 2019-02-14 2022-11-15 广州六顺生物科技股份有限公司 喹啉衍生物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物

Also Published As

Publication number Publication date
KR20230005190A (ko) 2023-01-09
TW202208335A (zh) 2022-03-01
WO2021222673A1 (en) 2021-11-04
JP2023524692A (ja) 2023-06-13
AU2021263474A1 (en) 2022-11-17
CO2022015205A2 (es) 2022-10-31
MX2022013528A (es) 2022-11-16
US20230192619A1 (en) 2023-06-22
IL297684A (en) 2022-12-01
BR112022021712A2 (pt) 2022-12-06
CA3176042A1 (en) 2021-11-04
CR20220551A (es) 2022-12-07
EP4143169A1 (en) 2023-03-08
CL2022003008A1 (es) 2023-06-23
CN115461328A (zh) 2022-12-09

Similar Documents

Publication Publication Date Title
PE20230110A1 (es) Procesos para la preparacion de un inhibidor de cinasa
CO6140053A2 (es) Proceso para fabricar 2-amino-5-halobenzamidas 3-sustituidas
CO6180506A2 (es) Inhibidores de la proteasa ns3 del hcv
AR079491A1 (es) Metodos de sintesis de inhibidores del factor xa tal como el betrixaban y composiciones farmaceuticas que contienen la base libre de betrixaban o su sal sustancialmente pura.
AU2004249511B2 (en) Processes for the preparation of 1-[(benzoimidazole-1yl) quinolin-8-yl] piperidin-4-ylamine derivatives
AR040773A1 (es) Pirazoles utiles como inhibidores de gsk-3
PE20050158A1 (es) Compuestos inmunosupresores y composiciones
NO20072198L (no) Korrosjons- og gasshydratinhibitorer med foroket biologisk nedbrytbarhet og redusert toksisitet
AR083953A1 (es) Compuestos para tratar enfermedades neurodegenerativas
PE20070051A1 (es) Serin-amidas sustituidas con heteroaroilo
NI201000049A (es) Método para producir 2'-desoxi-5-azacitidina (decitabina)
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR054088A1 (es) Triazoles como inhibidores de proteinquinasas. composiciones farmaceuticas
AR068538A1 (es) Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido
PE20110075A1 (es) Sintesis de compuestos de ester borico
DOP2007000022A (es) Derivados de n-heteroaril-carboxamidas tricíclicas que contienen un resto bencimidazol, su preparación y su aplicación en terapéutica
AR074821A1 (es) Proceso para preparar entecavir e intermediario para dicho proceso
PE20060650A1 (es) Metodo para preparar irbesartan e intermediarios del mismo
PE20091359A1 (es) Proceso de preparacion de compuestos organicos intermediarios de inhibidores de renina
AR048043A1 (es) Metodo para producir compuestos de aminifenol
PE20120223A1 (es) Compuestos heterociclicos como inhibidores del transportador de glicina-1 (glyt-1)
CO5611125A2 (es) Derivados de azetidina como antagonistas del receptor ccr-3
PE20020798A1 (es) COMPUESTO LACTAMICO QUE INHIBE LA LIBERACION DE PEPTIDO ß-AMILOIDE Y/O SU SINTESIS
AR059375A1 (es) Procedimiento para produccion de 5-alcoxi-4-hidroximetilpirazol y compuestos
AR046041A1 (es) Procedimiento para la preparacion de compuestos heterociclicos n-amino sustituidos